Preclinical evidence supports BPC-157s ability to: Heal gastric and intestinal ulcers Restore tight junction integrity in leaky gut models Protect against NSAID- and alcohol-induced GI damage Modulate inflammatory responses in colitis and Crohns Support microvascular circulation and enteric nerve health Across nearly all models of gastrointestinal injury, BPC-157 promoted effective healing without toxicity, making it one of the most promising peptides for gut repair. Sikiric, P
however, this program was discontinued in April 2025 following a potential drug-induced liver injury signal and earlier tolerability concerns, leaving orforglipron as the leading oral small-molecule GLP-1RA in late-stage development
PubMed laboratory research record [PMID: 2441515] PubMed record related to this compound for laboratory literature review
This study was performed at Masaryk University as part of the project Preclinical and clinical research at the Institute of Pharmacology: Pharmacokinetics, behavioral neuropsychopharmacology, and personalized pharmacotherapy number MUNI/A/1819/2025 with the support of the Specific University Research Grant, as provided by the Ministry of Education, Youth and Sports of the Czech Republic in the year 2026
Alpha-Lipoic Acid: This helps the body regenerate glutathione after it has been used up
Individuals Taking Medications: While no documented drug interactions exist, anyone taking prescription medications should inform their healthcare provider before adding BPC-157 or any supplement to their regimen